Akzo Nobel India's (NSE:AKZOINDIA) Shareholders May Want To Dig Deeper Than Statutory Profit

The recent earnings posted by Akzo Nobel India Limited (NSE:AKZOINDIA) were solid, but the stock didn't move as much as we expected. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

earnings-and-revenue-history
NSEI:AKZOINDIA Earnings and Revenue History May 22nd 2025
Advertisement

Examining Cashflow Against Akzo Nobel India's Earnings

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. This ratio tells us how much of a company's profit is not backed by free cashflow.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".

For the year to March 2025, Akzo Nobel India had an accrual ratio of 0.24. Unfortunately, that means its free cash flow fell significantly short of its reported profits. Indeed, in the last twelve months it reported free cash flow of ₹2.0b, which is significantly less than its profit of ₹4.30b. Akzo Nobel India's free cash flow actually declined over the last year, but it may bounce back next year, since free cash flow is often more volatile than accounting profits.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Akzo Nobel India's Profit Performance

Akzo Nobel India's accrual ratio for the last twelve months signifies cash conversion is less than ideal, which is a negative when it comes to our view of its earnings. Therefore, it seems possible to us that Akzo Nobel India's true underlying earnings power is actually less than its statutory profit. Nonetheless, it's still worth noting that its earnings per share have grown at 48% over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. At Simply Wall St, we found 2 warning signs for Akzo Nobel India and we think they deserve your attention.

This note has only looked at a single factor that sheds light on the nature of Akzo Nobel India's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:JSWDULUX

JSW Dulux

Manufactures, distributes, and sells paints and coatings in India and internationally.

Flawless balance sheet with solid track record and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7056.5% undervalued
23 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$317.225.0% undervalued
11 users have followed this narrative
6 users have commented on this narrative
6 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0539.8% undervalued
6 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
TO
Tokyo
OKTA logo
Tokyo on Okta ·

Good foundation, but now it's all about the next steps

Fair Value:US$15120.6% undervalued
82 users have followed this narrative
7 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

VA
Valtersa
ZVRA logo
Valtersa on Zevra Therapeutics ·

Discounted Exit Multiple Approach (DEM)

Fair Value:US$15.411.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SU
INTC logo
Suen on Intel ·

Intel Story

Fair Value:US$500.9378.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
VA
Valtersa
4018 logo
Valtersa on Almoosa Health ·

Normalized Earnings-Based Relative Valuation with a Discounted Forward Exit Multiple

Fair Value:ر.س148.0219.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7447.8% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9723.4% undervalued
57 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1932.6% undervalued
48 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative